Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA approves Reclast to prevent osteoporosis in postmenopausal women with convenient less frequent dosing
Novartis, 06/02/09
Reclast Injection has been approved by the US Food and Drug Administration as the first and only therapy to prevent postmenopausal osteoporosis for two years with a single dose. Reclast, or Aclasta as it is known outside the US, is already approved in more than 80 countries including the US and EU as a once-yearly infusion for the treatment of postmenopausal osteoporosis.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Article Search
Sponsor